164 related articles for article (PubMed ID: 32619635)
1. Safety assessment of metarrestin in dogs: A clinical candidate targeting a subnuclear structure unique to metastatic cancer cells.
Bourdi M; Rudloff U; Patnaik S; Marugan J; Terse PS
Regul Toxicol Pharmacol; 2020 Oct; 116():104716. PubMed ID: 32619635
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras
Vilimas T; Wang AQ; Patnaik S; Hughes EA; Singleton MD; Knotts Z; Li D; Frankowski K; Schlomer JJ; Guerin TM; Springer S; Drennan C; Dextras C; Wang C; Gilbert D; Southall N; Ferrer M; Huang S; Kozlov S; Marugan J; Xu X; Rudloff U
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1067-1080. PubMed ID: 30306263
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
[TBL] [Abstract][Full Text] [Related]
4. Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis.
Frankowski KJ; Wang C; Patnaik S; Schoenen FJ; Southall N; Li D; Teper Y; Sun W; Kandela I; Hu D; Dextras C; Knotts Z; Bian Y; Norton J; Titus S; Lewandowska MA; Wen Y; Farley KI; Griner LM; Sultan J; Meng Z; Zhou M; Vilimas T; Powers AS; Kozlov S; Nagashima K; Quadri HS; Fang M; Long C; Khanolkar O; Chen W; Kang J; Huang H; Chow E; Goldberg E; Feldman C; Xi R; Kim HR; Sahagian G; Baserga SJ; Mazar A; Ferrer M; Zheng W; Shilatifard A; Aubé J; Rudloff U; Marugan JJ; Huang S
Sci Transl Med; 2018 May; 10(441):. PubMed ID: 29769289
[TBL] [Abstract][Full Text] [Related]
5. Determination of metarrestin (ML-246) in human plasma for a first-in-human clinical pharmacokinetic application by a simple and efficient uHPLC-MS/MS assay.
Richardson WJ; Zimmerman SM; Reno A; Corvalan Cabanas N; Arisa O; Rudloff U; Figg WD; Peer CJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 May; 1224():123738. PubMed ID: 37196527
[TBL] [Abstract][Full Text] [Related]
6. Oral repeated-dose toxicity studies of BIA 10-2474 in beagle dogs.
Hardisty JF; Harris SB; Hayes WA; Weber K
Regul Toxicol Pharmacol; 2020 Mar; 111():104555. PubMed ID: 31874201
[TBL] [Abstract][Full Text] [Related]
7. 28-day repeated dose toxicity and toxicokinetics study on new melatonergic antidepressant GW117 in beagle dogs.
Gao M; Chen K; Gu W; Liu X; Liu T; Ying Y; Cao C; Zhang Y; Zhang D; Yang G
J Appl Toxicol; 2023 Apr; 43(4):577-588. PubMed ID: 36268681
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks.
Wallery JJ; Kale VP; Novak J; Gibbs S; Do MT; McKew JC; Terse PS
Toxicol Appl Pharmacol; 2021 Nov; 430():115680. PubMed ID: 34411581
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
10. GMP-grade α-TEA lysine salt: a 28-Day oral toxicity and toxicokinetic study with a 28-Day recovery period in Beagle dogs.
Guerrouahen BS; Hahn T; Alderman Z; Curti B; Urba W; Akporiaye ET
BMC Cancer; 2016 Mar; 16():199. PubMed ID: 26957307
[TBL] [Abstract][Full Text] [Related]
11. A safety study of a novel photosensitizer, sinoporphyrin sodium, for photodynamic therapy in Beagle dogs.
Lin N; Li C; Wang Z; Zhang J; Ye X; Gao W; Wang A; Jin H; Wei J
Photochem Photobiol Sci; 2015 Apr; 14(4):815-32. PubMed ID: 25671327
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
13. Safety and toxicology assessment of sodium nitrite administered by intramuscular injection.
Miller L; Hébert CD; Grimes SD; Toomey JS; Oh JY; Rose JJ; Patel RP
Toxicol Appl Pharmacol; 2021 Oct; 429():115702. PubMed ID: 34464673
[TBL] [Abstract][Full Text] [Related]
14. Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats.
Shim HJ; Kim YC; Jang JM; Park KJ; Kim DH; Kang KK; Ahn BO; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2003 Dec; 24(9):409-18. PubMed ID: 14689469
[TBL] [Abstract][Full Text] [Related]
15. Investigational new drug-directed toxicology and pharmacokinetic study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) in Beagle dogs.
Papadopoulou MV; Bloomer WD; Torti VR; Page JG
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):511-22. PubMed ID: 20074266
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion.
Brown AP; Courtney CL; Criswell KA; Holliman CL; Evering W; Jessen BA
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1091-101. PubMed ID: 18509643
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
Ruperto N; Brunner HI; Zuber Z; Tzaribachev N; Kingsbury DJ; Foeldvari I; Horneff G; Smolewska E; Vehe RK; Hazra A; Wang R; Mebus CA; Alvey C; Lamba M; Krishnaswami S; Stock TC; Wang M; Suehiro R; Martini A; Lovell DJ; ;
Pediatr Rheumatol Online J; 2017 Dec; 15(1):86. PubMed ID: 29282090
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis.
Frankowski KJ; Patnaik S; Wang C; Southall N; Dutta D; De S; Li D; Dextras C; Lin YH; Bryant-Connah M; Davis D; Wang F; Wachsmuth LM; Shah P; Williams J; Kabir M; Zhu E; Baljinnyam B; Wang A; Xu X; Norton J; Ferrer M; Titus S; Simeonov A; Zheng W; Mathews Griner LA; Jadhav A; Aubé J; Henderson MJ; Rudloff U; Schoenen FJ; Huang S; Marugan JJ
J Med Chem; 2022 Jun; 65(12):8303-8331. PubMed ID: 35696646
[TBL] [Abstract][Full Text] [Related]
19. Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
Robertson DG; Breider MA; Milad MA
Toxicol Sci; 2001 Feb; 59(2):324-34. PubMed ID: 11158726
[TBL] [Abstract][Full Text] [Related]
20. Subacute toxicity and toxicokinetics of a new antibiotic, DW-224a, after single and 4-week repeated oral administration in dogs.
Han J; Kim JC; Chung MK; Kim B; Choi DR
Biol Pharm Bull; 2003 Jun; 26(6):832-9. PubMed ID: 12808295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
